Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 26, 2000

View Archived Issues

Intracel's phase III trial for bladder cancer approved by FDA

Vion updates clinical progress and development agreements

Guilford reacquires rights to Gliadel Wafer

MitoKor and UCSD receive BioSTAR grant for osteoarthritis research

LF-16-0687MS reduces brain edema and neurological severity scores in closed head trauma

ASA 2000: binding, functional and physicochemical properties of TRK-820 and TAN-684

Human studies confirm excellent safety and suitable pharmacokinetics of parecoxib

Phase II trial with EBV vaccine begins, triggering milestone payment to Aviron

Bradykinin B2 antagonist effective in rat model of head trauma

Remicade recommended for approval in Europe for broader application

CHEST 2000: anti-TNF MAb improves survival, reduces organ dysfunction in sepsis

FDA grants priority review status to Genelabs' NDA for new lupus therapy

Organon characterizes water-soluble general anesthetic advanced to early clinical trials

Update on proposed Novo Nordisk demerger

SmithKline Beecham's combination pediatric vaccine approved in E.U.

Novel immunosuppressants revealed by Japanese lab

Thiadiazole STAT6 activation inhibitors designed at Sumitomo

Dainippon describes new, water-soluble neutrophil elastase inhibitors

Bayer discloses sulfonamides and their use in the treatment of HCMV infections

U.S. patent covers new series of GH secretagogues from Novo Nordisk

Preparation and use of protease inhibitor series particularly useful in bone diseases

Novel treatments for labor pain revealed in recent patent by AstraZeneca

Caspase 3 inhibitors from Merck Frosst demonstrate antiischemic activity

Astex Technology and Janssen enter second research collaboration

Researchers discover potential new target for antidepressant drugs

Gaucher's disease therapy receives European orphan drug status

Inflammatory and autoimmune disease treatment enters phase I testing

Leukemia treatment designated an orphan drug in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...